Medical - Diagnostics & Research · NYSE
当前价格
$163.85
内在价值
使用下方计算器估算
对 IQVIA Holdings Inc. 运行 PE 市盈率估值，自动填充盈利数据，可调节目标 PE，即时获得公允价值估算。
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Earnings Yield
4.88%
ROE (TTM)
22.3%
基于过去 12 个月的数据，IQV 每股收益为 N/A，市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。
IQV 的过去 12 个月市盈率反映投资者为 IQVIA Holdings Inc. 每一美元收益所支付的价格。该指标在与Medical - Diagnostics & Research同类公司和公司自身历史区间对比时最有意义。
IQV 是否被高估取决于将其市盈率与Medical - Diagnostics & Research同类公司、历史均值和增长预期比较。高于行业均值的 PE 可能暗示高估，但高增长公司通常有更高的估值倍数。建议配合 DCF 模型获得更完整的判断。
对 IQVIA Holdings Inc. 使用 PE 估值的步骤：(1) 将当前市盈率与Medical - Diagnostics & Research中位数对比评估相对定价，(2) 查看 PEG 比率以调整增长预期，(3) 参考 5 年 PE 历史区间判断当前位置，(4) 用目标 PE 乘以前瞻 EPS 估算公允价值。这种相对估值方法与 DCF 的绝对估值互为补充。
PEG 比率将市盈率除以预期盈利增速，提供增长调整后的估值指标。PEG 低于 1.0 可能表明相对于增长被低估，高于 2.0 可能暗示高估。PEG 对盈利增长稳定可预测的公司最为可靠。
PE 市盈率给出快速的相对定价——IQV 相对于Medical - Diagnostics & Research同类的估值水平。DCF 基于预期自由现金流提供绝对价值。对于 IQV，ROE 达到 22.3%，两种方法都值得使用——PE 做市场对比，DCF 验证基本面是否支撑当前价格。两种方法各有盲区：PE 忽略了资本结构和现金流质量，DCF 则对增长率和折现率假设非常敏感。
